Data from certain leukemias as well as brain and breast cancer indicate that there is a small population of tumor cells with 'stem cell' characteristics and the capacity for self-renewal. The self-renewing cells have many of the properties of normal stem cells and have been termed 'cancer stem cells'. These cancer stem cells make up as few as 1% of the cells in a tumor, making them difficult to detect and study. Like normal stem cells, cancer stem cells have a number of properties permitting them to survive traditional cancer chemotherapy and radiation therapy. These cells express high levels of ATP-binding cassette (ABC) drug transporters, providing for a level of resistance; are relatively quiescent; have higher levels of DNA repair and a lowered ability to enter apoptosis. Combined cancer therapy approaches targeting the cancer stem cells and the non-stem cells may be developed with increased efficacy. Efforts to target the Hedgehog/ Patched pathway, critical to embryonic growth and differentiation, and the ABCG2 drug efflux transporter will be presented.
Most cancer cells divide rapidly and many cancer cell lines can be grown indefinitely in culture as immortal cells, just as can embryonic stem cells. Embryonic carcinomas and teratocarcinomas are tumors derived from embryonic cells capable of differentiating into cells of many lineages. Beatrice Mintz and Ralph Brinster independently demonstrated that teratocarcinomas could give rise to normal chimeric mice (Mintz and Illmensee, 1975; Brinster, 1976) , documenting the potential totipotentiality of some tumor cells.
In 1994, the presence of cancerous stem cells in acute lymphocytic leukemia was documented by cloning such cells and documenting their self-renewing capacity (Lapidot et al., 1994) . The cloning of the Patched (PTCH) gene as a tumor suppressor gene directly connected early embryonic development to tumorigenesis (Hahn et al., 1996; Johnson et al., 1996) . The PTCH protein is a membrane protein and is the receptor for the Hedgehog (HH) family of signaling molecules. PTCH and the HH proteins play an important role in the cell fate and patterning of early embryonic cells. Alterations in the growth regulation of stem cells and their progeny was proposed to explain the role of the PTCH gene in causing basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome (Dean, 1997) .
A self-renewing cell population (cancer stem cells) have been identified in solid tumors such as breast and brain (Al-Hajj et al., 2003; Hemmati et al., 2003) . These cancer stem cells represent approximately 1% of the tumor and are the only cells in the tumor generating tumors into nude mice. Additional studies have also demonstrated the presence of a minor population of cells in cell lines with some of the same properties as stem cells (Hirschmann-Jax et al., 2004; Kondo et al., 2004) . Many researchers now suspect that all cancers are composed of a mixture of stem cells and proliferative cells with a limited lifespan (Al-Hajj and Clarke, 2004; Dean et al., 2005) .
The implications of this research are potentially far reaching. The remission of many cancers following therapy could be the result of the survival of the cancer stem cells. Therefore, it is critical to fully characterize these cells and to develop approaches to eliminate these cells without excessive toxicity to normal stem cells.
Inhibiting the HH/PTCH pathway
For those solid tumors composed of a minor population of self-renewing (stem) cells and a large fraction of nonrenewing cells, the tumors that regress following radiation and chemotherapy treatments are not the result of a rare cell evolving from within the tumor, but are the regrowth of the cancer stem cells. Cancer stem cells can accumulate genetic changes rendering them more drug resistant, radiation resistant or aneuploid. Because cures are achieved for some types of cancer, the cancer stem cells must be eliminated by some of the current therapies. The non-self-renewing cells in a tumor may play a role in maintaining or stimulating the stem cells, thereby forming a 'tumor niche'. Rapid regression of a tumor following cytotoxic therapy could lead to a disruption of the tumor niche and subsequent death of the cancer stem cells. For many tumors, there is also an important role played by immune surveillance (Nakachi et al., 2004) , and reducing the size of the tumor may allow the immune system to more efficiently eliminate the remaining cells.
Targeted therapies directly suppressing or eliminating cancer stem cells may synergize with established therapies and increase efficacy. For example, angiogenesis is undoubtedly critical in providing the blood supply of the cancer stem cells, and therapies designed to inhibit the development of blood vessels are likely to be effective (Folkman, 2002) .
One of the protective mechanisms against toxins that stem cells possess is the expression of one or more ATPbinding cassette (ABC) transporters. These efflux pumps are highly expressed in normal stem cells and provide protection from xenobiotic toxins (Gottesman et al., 2002) . The ABCG2 and ABCB1/MDR1 genes are expressed in the normal stem cells and in most tumor stem cells (Zhou et al., 2001; Kim et al., 2002; Scharenberg et al., 2002) . The activity of these transporters can be followed through the transport of fluorescent dyes like rhodamine and Hoecht 33342. This property has allowed stem cells to be separated from non-stem cells on fluorescence-activated cell sorters (FACS) (Goodell et al., 1996) . These cells have been termed 'side-population' (SP) cells as they are found on the side of the distribution of cells on the cell sorter. SP cells have also been identified in many tumor cell lines and shown, in a few cases, to be highly tumorigenic The combined use of chemotherapy drugs and inhibitors targeting ABC transporters could be employed to selectively and more efficiently kill cancer stem cells (Dean et al., 2005) . There are highly specific inhibitors of ABCB1 in clinical use and some of these inhibitors also inhibit ABCG2 (Robey et al., 2004) . In addition, a high throughput cell-based screen for ABCG2 has been established and is being used to identify new inhibitors (Henrich et al., 2006) . Inhibition of drug transporters is likely to cause toxicity of the patient's normal stem cells, particularly those of the bone marrow. In addition, both ABCG2 and ABCB1 play a role in maintaining the blood-brain barrier. Therefore, these inhibitors would have to be carefully titrated to avoid excessive side effects.
Another approach to inhibit cancer stem cells is to target pathways essential for the growth and maintenance of normal stem cells. Because of developmental and embryological studies in Drosophila, mice, Caenorhabditis elegans, zebrafish and other model systems, considerable information is known about the growth regulatory pathways important to embryonic cells (Nusslein-Volhard and Wieschaus, 1980) . One of these pathways is controlled by the HH and WNT signaling molecules, and contains several genes that can act as either tumor suppressor genes or oncogenes (Dean, 1997) . PTCH is the receptor for HH molecules and the PTCH gene is mutated in patients with an inherited disorder, nevoid basal cell carcinoma syndrome Hahn et al., 1996; Johnson et al., 1996) . The PTCH gene is also mutated in nearly all spontaneous basal cell carcinomas as well as some medulloblastomas, rhabdomyomas and rhabdomyosarcomas Bale and Yu, 2001; Tostar et al., 2006 Tostar et al., no. 1121 . The mammalian HH genes (IHH, SHH, DHH) are highly expressed in many cancer cell lines including small cell lung, pancreas, gastric, breast and prostate Thayer et al., 2003; Watkins et al., 2003; Karhadkar et al., 2004) . Expression of the HH ligand and mutational inactivation of PTCH both have the effect of constitutive activation of smoothened (SMO) a G-protein-coupled receptor family protein that is regulated by PTCH. HH pathway disregulation has been proposed to be a component in stem cell activation in cancers and therefore represents an attractive target for cancer therapy (Dean, 2006) .
A steroid-like compound, cyclopamine (James et al., 2004) , binds to and inhibits the SMO protein and inhibits the growth of cells and tumors with activated HH signaling (Chen et al., 2002) . The DU-145 and PC-3 human prostate tumor cell lines grown as xenografts in mice were eliminated following 21 days of treatment with cyclopamine (Karhadkar et al., 2004) . Furthermore, UV-induced basal cell carcinomas in P53À/À mice were inhibited by low levels of cyclopamine given in the drinking water (Athar et al., 2004) . Recently, it has been demonstrated that vitamin D3 is a critical signaling molecule between PTCH and SMO. PTCH normally secretes vitamin D3 and this molecule inhibits SMO on that cell as well as adjacent cells (Bijlsma et al., 2006) . HHs function by inhibiting this secretion, causing a release from repression. Cyclopamine competes for the binding of vitamin D3 on SMO and so appears to act in a similar manner. It is likely that vitamin D3 and/or other steroidal analogues could have a similar effect and be candidate anticancer compound.
To extend these studies, we have verified that cyclopamine inhibits the proliferation of human prostate and gastric cancer cell lines (Figures 1 and 2) . Analysis of HH/PTCH genes shows that the expression of SHH, SUFU, PTCH, GLI2 and GLI3 are significantly down-regulated by cyclopamine treatment. Therefore, expression of the mRNA or protein of these genes could be useful for evaluating the effectiveness of targeted therapy in human cancers.
Future research
The isolation of cancer stem cells in solid tumors has important implications for both basic and applied cancer research. Most studies of tumors to determine gene expression, protein expression, as well as many phenotypic assays have been performed on whole tumors or bulk cell cultures. If the critical cell population to assess is a small population of tumor stem cells, then these experiments may need to be reinterpreted.
Several important questions remain to be answered concerning cancer stem cells. Do the side population cells isolated from cell lines (Hirschmann-Jax et al., 2004; Kondo et al., 2004) bear a relationship to cancer stem cells? One unique property of cancer cells is the ability, like normal stem cells, to grow in soft agar cultures (Hamburger and Salmon, 1977) . Only a fraction of cells in a tumor cell culture can form a colony in soft agar. Are the cells forming soft agar colonies cancer stem cells? Again, a cell forming a colony in soft agar must have self-renewal activity. Soft agar assays could be renewed for the screening of drugs.
The vast majority of cancer fatalities are due to metastasis -the spread of the initial tumor to other sites. Stem cells, particularly the cells of the neural crest, normally migrate (invade) throughout the developing embryo. The neural crest gives rise to the precursors of many metastatic cancers including melanoma, neuroblastoma and small-cell lung tumors. Is the metastatic ability of tumor cells an innate property of the cancer stem cells? If so then the characterization of germ cell migration could reveal new insights into metastasis. Anticancer stem cell therapies could be effective at the suppression of metastasis, resulting in substantial increases in survival of the patient. 
